Xelum R&D on world tour

Bosch Packaging Technology’s Xelum R&D for the continuous production of oral solid dosage (OSD) forms holds substantial potential: since it was first introduced to selected customers in 2018, the compact, innovative machine has attracted considerable interest. Now Bosch is taking the Xelum production platform’s ‘little sister’ on a world tour. The Xelum R&D starts the great journey in New York. From there it goes via Nuremberg to Tokyo and Frankfurt. Its last destination is Moscow. Thus, our machine will travel to 3 continents.

A shorter path from the lab to production

The Xelum R&D significantly shortens the path from the lab to production. But what’s its secret?
The new laboratory unit uses the same components and process parameters as the Xelum production platform from Bosch. This paves the way for a direct 1-to-1 transfer and does away with the need for a scale-up, which also means pharmaceutical manufacturers can accelerate development and reduce time-to-market. In addition, DoE (Design of Experiment) software support and automation round out the system’s user-friendly handling.
In contrast to the commonly used mass flow rate, excipients and active ingredients are precisely dosed as a discrete mass in the Xelum R&D. The system doses, mixes and granulates individual packages (‘X-keys’), which continuously run through the process chain and are successively removed from the machine.
In this regard, Bosch relies on fluid bed processors developed by its subsidiary Hüttlin. Since granulating and drying take place in the same process unit, there’s no need to transfer wet granules – which also means that production quantities ranging from less than 250 grams to ten kilograms can be processed per hour using an automated cycle. Production with highly potent active ingredients is an available option.

The kick off of the Xelum R&D presentation was at the Interphex in New York in the beginning of April. At the international trade fair for drug, cosmetic and detergent development and manufacturing, visitors from around the world were able to view the Xelum R&D for the first time in the United States.

New York, Interphex – April 2-4

Immediately afterwards, the Xelum R&D traveled to the Powtech in Nuremberg, where it made an outstanding impression between powder, granulate and bulk solids technologies and defied the time difference to New York.

Nuremberg, Powtech – April 9-11

With the passport and many beautiful memories in the luggage, the Xelum R&D is now on its way to Japan, where it will be seen at the Interphex from 3.-5. July.

Tokyo, Interphex Japan – July 3-5

After a calm overseas journey by plane, the Xelum R&D has arrived very well in Tokyo. For the first time, it spent three exciting days at the Interphex show Japan. The German-Japanese pharma solid sales team presented the great potential of continuous production of oral solid dosage (OSD) with the Xelum R&D and attracted a lot of attention.

Now our machine can live the good life since the next show will be in November, where it will be seen at the CPHI / P-Mec worldwide in Frankfurt.


The Xelum R&D tour stops at a glance:

  • Interphex in New York (April 2-4)
  • Powtech in Nuremberg (April 9-11)
  • Interphex Japan in Tokyo (July 3-5)
  • CPhI / P-Mec worldwide in Frankfurt (November 5-7)
  • Pharmtech in Moscow (November 19-22)

Nicole König
Marketing Manager
Phone: +49 7951 402-648

Top of page